TABLE 3.
Characteristics of patients with carbapenem-resistant infections treated with compassionate-use CAZ-AVI
| Characteristic | Value (n = 38)a |
|---|---|
| Demographic characteristics | |
| Age in yr, median (IQRb) | 61 (47–67) |
| Male sex | 25 (65.8) |
| Location before hospitalization | |
| Home | 33 (86.8) |
| Transferred from another hospital | 5 (13.2) |
| Comorbidities | |
| Transplant recipient | 5 (13.2) |
| Diabetes mellitus | 8 (21.1) |
| Immunosuppressionc | 10 (26.3) |
| Renal disease | 7 (18.4) |
| Cardiovascular disease | 11 (28.9) |
| McCabe score of >1 | 19 (50.0) |
| Infection characteristics | |
| Organism and carbapenemase | |
| Klebsiella pneumoniae | |
| KPC | 22 |
| OXA-48 | 12 |
| Klebsiella oxytoca (KPC) | 1 |
| Escherichia coli (OXA-48) | 1 |
| Pseudomonas aeruginosa | 2 |
| Hospital-acquired infection | 34 (89.5) |
| Bacteremia | 26 (68.4) |
| Polymicrobial infection | 11 (29.0) |
| Life-threatening infection (high risk of death within 30 days) | 23 (60.5) |
| Antibiotics before CAZ-AVI | |
| Received antibiotics before CAZ-AVI for this infection | 36 (94.7) |
| Days of antibiotic treatment before CAZ-AVI, median (IQR) | 13 (7–31) |
| No. of antibiotics before CAZ-AVI, median (IQR) | 3 (3–4) |
| Other treatments before CAZ-AVI | |
| Surgery to remove the source of infection | 16 (42.1) |
| Removal of foreign body involved in infection | 9 (23.7) |
| Clinical status at start of CAZ-AVI treatment | |
| Mechanical ventilation | 14 (36.8) |
| Vasopressor support | 17 (44.7) |
| Unconscious | 12 (31.6) |
| CAZ-AVI treatment | |
| Days of treatment, median (IQR) | 16 (14–21) |
| Extended infusion | 36 (94.7) |
| Concurrent antibiotic treatmentd | 25 (65.8) |
| Received standard CAZ-AVI dose | 24 (63.2) |
a
Values are number (%) of patients unless indicated otherwise.
b
IQR, interquartile range.
c
Immunosuppression was defined as posttransplant, chemotherapy in past 6 weeks, systemic steroids (>20 mg of prednisone) or other immunosuppressive agents in past 2 weeks, absolute neutrophil count of <500/μl, or HIV/AIDS.
d
During CAZ-AVI treatment, patient received another antibiotic to which organism was nonresistant in vitro.